Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects able and willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF)~2. Male or female subjects of non-child-bearing potential aged ≥ 40 years~3. Subjects with a chest HRCT performed within 12 months prior to screening~4. Subjects with IPF diagnosed by a multidisciplinary team~5. Subjects with: a. forced vital capacity (FVC) ≥50% predicted of normal AND b. Diffusing capacity for the lungs for carbon monoxide (DLCO) ≥ 30% predicted of normal corrected for hemoglobin~6. Subjects with a forced expiratory volume in 1 second (FEV1)/FVC (Tiffeneau-Pinelli index) ratio ≥ 0.70 (based on pre-bronchodilator spirometry~7. Subjects on stable supportive care~8. Subjects in stable condition~Exclusion Criteria:~1. Subjects with know hypersensitivity to any of the study drug ingredients~2. Subjects with a history of or current immunosuppressive condition~3. Subjects with a history of malignancy within the past 5 years~4. Subjects with clinically significant abnormalities on ECG~5. Subjects with acute IPF exacerbation within 6 weeks prior to screening~6. Subjects with a lower respiratory tract infection requiring antibiotics with 4 weeks prior to screening~7. Smoking within 3 months pre-screening~8. Interstitial lung disease~9. History of lung volume reduction surgery or lung transplant~10. Unstable cardiac or pulmonary disease other than IPF within 6 months prior to screening~11. Subjects with abnormal liver function~12. Subjects with abnormal renal function

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLPG1690 600 mg once daily (QD) (Type: EXPERIMENTAL): None
- Placebo QD (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).